Skip to content
Home
Company
About Us
Leadership
Management
Board of Directors
Scientific
Advisory Board
Science
Overview
Evorpacept
Publications
Pipeline
Pipeline
Clinical Trials
Expanded
Access Policy
Careers
Current Jobs
How to Apply
Investors
Overview
News & Events
Stock Information
Corporate Governance
Financials & Filings
IR Resources
Contact
ALX148 Enhances the Depth and Durability of Response to Multiple AML Therapies
Post navigation
Previous:
Targeting the Myeloid Checkpoint Receptor SIRPα Potentiates Innate and Adaptive Immune Responses to Promote Anti‑Tumor Activity
Next:
ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma; ASPEN-01
